Cargando…

Identification of TMB, CD8 T‐cell abundance, and homologous repair pathway mutation frequency as predictors of the benefit–toxicity ratio of anti‐PD‐1/PD‐L1 therapy

Detalles Bibliográficos
Autores principales:	Long, Junyu, Yang, Xu, Bian, Jin, Wang, Dongxu, Wang, Anqiang, Lin, Yu, Zheng, Mingjun, Zhang, Haohai, Sang, Xinting, Zhao, Haitao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597891/ https://www.ncbi.nlm.nih.gov/pubmed/34841682 http://dx.doi.org/10.1002/ctm2.598

Ejemplares similares

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape
por: Long, Junyu, et al.
Publicado: (2022)

Combination regimens with PD-1/PD-L1 immune checkpoint inhibitors for gastrointestinal malignancies
por: Wang, Dongxu, et al.
Publicado: (2019)

Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy
por: Long, Junyu, et al.
Publicado: (2021)

Classification of gallbladder cancer by assessment of CD8(+) TIL and PD-L1 expression
por: Lin, Jianzhen, et al.
Publicado: (2018)

PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
por: Long, Junyu, et al.
Publicado: (2017)

Efficacy and safety of lenvatinib combined with PD-1/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer
por: Zhu, Chengpei, et al.
Publicado: (2023)

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC
por: Alessi, Joao V., et al.
Publicado: (2023)

Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis
por: Zhu, Jiaxin, et al.
Publicado: (2019)

The Comprehensive Analyses of Genomic Variations and Assessment of TMB and PD-L1 Expression in Chinese Lung Adenosquamous Carcinoma
por: Cheng, Yong, et al.
Publicado: (2021)

ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors
por: Nie, Wei, et al.
Publicado: (2022)

PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers
por: Mao, Jinzhu, et al.
Publicado: (2021)

Local and abscopal responses in advanced intrahepatic cholangiocarcinoma with low TMB, MSS, pMMR and negative PD-L1 expression following combined therapy of SBRT with PD-1 blockade
por: Liu, Xiaoliang, et al.
Publicado: (2019)

TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy
por: Eckardt, Julia, et al.
Publicado: (2022)

Genomic Variations and Immune-Related Features of TMB, PD-L1 Expression and CD8(+) T Cell Infiltration in Chinese Pulmonary Sarcomatoid Carcinoma
por: Zhang, Chenyue, et al.
Publicado: (2022)

Relationship among DDR gene mutations, TMB and PD-L1 in solid tumour genomes identified using clinically actionable biomarker assays
por: Wang, Danyi, et al.
Publicado: (2023)

Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers
por: Hu, Chunhong, et al.
Publicado: (2021)

Baseline lesion number as an efficacy predictive and independent prognostic factor and its joint utility with TMB for PD-1 inhibitor treatment in advanced gastric cancer
por: Wei, Xiao-Li, et al.
Publicado: (2021)

Recent developments in PD-1/PD-L1 blockade research for gastroesophageal malignancies
por: Chen, Meng, et al.
Publicado: (2022)

Role of the PD-1 and PD-L1 axis in COVID-19
por: R Bonam, Srinivasa, et al.
Publicado: (2022)

Clinical benefit of neoadjuvant anti‐PD‐1/PD‐L1 utilization among different tumors
por: Li, Zhiyang, et al.
Publicado: (2021)

Pembrolizumab combined with anlotinib improves therapeutic efficacy in pulmonary sarcomatoid carcinoma with TMB-H and PD-L1 expression: a case report and literature review
por: Wu, Shugui, et al.
Publicado: (2023)

Dynamics of Neutrophils-to-Lymphocyte Ratio Predict Outcomes of PD-1/PD-L1 Blockade
por: Moschetta, Michele, et al.
Publicado: (2017)

Metabolic Tumor Volume Measured by (18)F-FDG PET/CT is Associated with the Survival of Unresectable Hepatocellular Carcinoma Treated with PD-1/PD-L1 Inhibitors Plus Molecular Targeted Agents
por: Wang, Xuezhu, et al.
Publicado: (2023)

Identification of hub genes involved in the development of hepatocellular carcinoma by transcriptome sequencing
por: Zheng, Yongchang, et al.
Publicado: (2017)

Serum cytokines and neutrophil-to-lymphocyte ratio as predictive biomarkers of benefit from PD-1 inhibitors in gastric cancer
por: Hou, Yidan, et al.
Publicado: (2023)

Lung cancer patients with chronic obstructive pulmonary disease benefit from anti-PD-1/PD-L1 therapy
por: Lin, Mao, et al.
Publicado: (2022)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

PD-1(T) TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC
por: Hummelink, Karlijn, et al.
Publicado: (2022)

Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
por: Tomlins, Scott A., et al.
Publicado: (2023)

CD8(+)PD-1(+) to CD4(+)PD-1(+) ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers
por: Duchemann, Boris, et al.
Publicado: (2022)

Abundant expression of TIM-3, LAG-3, PD-1 and PD-L1 as immunotherapy checkpoint targets in effusions of mesothelioma patients
por: Marcq, Elly, et al.
Publicado: (2017)

Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy
por: Broos, Katrijn, et al.
Publicado: (2018)

Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
por: Bulen, Benjamin J., et al.
Publicado: (2023)

Citrus Fruit Intake Substantially Reduces the Risk of Esophageal Cancer: A Meta-Analysis of Epidemiologic Studies
por: Wang, Anqiang, et al.
Publicado: (2015)

Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients
por: Yang, Xu, et al.
Publicado: (2023)

The changes in peripheral blood Th17 and Treg ratios in Hashimoto’s thyroiditis are accompanied by differential PD-1/PD-L1 expression
por: Fang, Jun, et al.
Publicado: (2022)

The relationship between different subtypes of KRAS and PD-L1 & tumor mutation burden (TMB) based on next-generation sequencing (NGS) detection in Chinese lung cancer patients
por: Yang, Ying, et al.
Publicado: (2022)

Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB
por: Sung, Meng-Ta, et al.
Publicado: (2022)

PD-1/PD-L1 inhibitors for advanced or metastatic cervical cancer: From bench to bed
por: Huang, Weijia, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_hemi14r1quqtcof6nnksm6groj